Menu
company
SLP concept
SLP therapy is synergistic
publications
technology
SLP technology
AMPLIVANT technology
pipeline
ISA101b (HPV16)
ISA103 (PRAME)
ISA104 (HBV)
ISA106 (SARS-CoV2)
MyISA®
clinical studies
partners
news archive
careers
contact
scientific advisory board
latest news
ISA to Present at the 4th Annual Virtual H.C. Wainwright HBV Conference on October 25th
October 24, 2023
First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
August 31, 2023
The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy
June 6, 2023
ISA to Present First Clinical Trial Data from the Phase II Study of ISA101b and Libtayo® (cemiplimab) Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023
May 25, 2023
ISA to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting
April 27, 2023